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Abstract
Lung cancer is the leading cause of cancer death worldwide and the use of novel agents, such as
sorafenib has now demonstrated activity in Non Small Cell Lung Cancer. We present a case of a
77-year-old Caucasian male with advanced adenocarcinoma of the lung, who was being treated on
clinical trial with single agent sorafenib. After seven weeks of treatment the patient presented to clinic
with difficulty walking. Physical exam revealed acral erythema with bollous formation on bilateral
soles of his feet. Otoscopic exam revealed bilateral external canal bullous lesion. The patient was
diagnosed with plantar erythrodysesthesia with bullous otitis externa, a new toxicities in patients
being treated with sorafenib.
Introduction
Lung cancer is the leading cause of cancer death worldwide
[1]. Use of novel agents, such as sorafenib, a multitargeted
receptor tyrosine kinase inhibitor, have demonstrated
activity in non small cell lung cancer (NSCLC) [2-3].
Currently, the toxicities reported in NSCLC have been
similar to those reported in Renal Cell Carcinoma clinical
trials [4]. Here we present a case of new toxicity that
occurred on a relatively low dose of sorafenib.
Case presentation
A 77-year-old Caucasian male with advanced adenocarci-
noma of the lung, was being treated on clinical trial with
single agent sorafenib. He was started on 400 mg orally
twice a day and developed grade 3 hypertension after two
weeks of therapy and was subsequently dose reduced to
200 mg orally twice a day. During his fifth week of
treatment the patient reported to a mild decrease in his
hearing as well as mild facial erythema, grade 1. Otoscopic
examination revealed bilateral mild erythematous skin in
the external auditory canal without evidence of skin
breakdown and bilateral impacted cerumen which was
managed with warm saline washes resulting in resolution
of his hearing deficit. After seven weeks of treatment the
patient presented to clinic with an acute complaint of
difficulty walking. Physical exam revealed acral erythema
with bollous formation along the pressure points of
bilateral soles of his feet. Otoscopic exam of bilateral
external auditory canal revealed a right ulcerated lesion
(Figure 1) and the left ear showed a ruptured bullous
lesion (Figure 2). Biopsy of the left ear lesion revealed no
evidence of necrosis, as well as no evidence of a viral,
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and without any history of ear canal trauma, a diagnosis of
plantar erythrodysesthesia with bullous otitis externa
associated with sorafenib was made. Sorafenib was with-
drawn and all toxicities resolved to grade 1 within one
week. Patient underwent scheduled imaging 8 weeks
from the start of sorafenib, prior to reinstitution of the
sorafenib, and was found to have progression of disease.
He was subsequently discontinued from this clinical trial.
Discussion
Sorafenib is a multi-tyrosine kinase inhibitor that targets
serine/threonine and receptor tyrosine kinases and has
been shown to decrease both tumor growth and angiogen-
esis [4]. Sorafenib has activity against the vascular
endothelial growth factor receptor (VEGFR-2, VEGFR-3),
platelet-derived growth factor receptor (PDGFR-beta),
stem cell factor receptor (c-KIT), and the RET, BRAF and
FLT-3 kinase pathways. The most common reported
adverse events are diarrhea, rash, fatigue, hypertension
and hand-foot-skin reactions [5].
Palmar and plantar erythrodysesthesia (hand-foot-skin
reactions) has been reported to occur in up to 30% of
patients being treated with monotherapy sorafenib for
clear cell renal cell carcinoma [5]. The mechanism of
which this syndrome occurs is unique from other acral
chemotherapy reactions (hand-foot syndrome). Che-
motherapies (i.e. liposomal doxorubicin, capecitabine)
causing acral reactions are believed to be secondary to high
concentrations of the drugs being secreted in the eccrine
glands [6]. The human body has a high concentration of
eccrine glands located in the palms and soles of the feet
[6]. The acral toxicities secondary to multi-tyrosine kinase
inhibitors occur in the palms and soles of the hands and
feet but distinctly appear along the pressure points of the
feet as well as along the sides and web areas of these
surfaces. The severity of the lesions has been shown to be
dose dependent and resolution of symptoms occurs with
withdrawal of the drug [7]. It has been proposed that this
occurs in this distinct pattern, which is different from
chemotherapy induced acral reactions, secondary to the
combination of the vascular anatomy within these areas,
the temperature gradient of these points and the increased
concentration of the eccrine glands [8]. The feet and hands
have a rich capillary network and use of the extremities
cause increases in blood flow to these areas [8].
The cercum glands in the external auditory canal are a
specialized variant of eccrine glands which function both
as apocrine and eccrine glands [9]. The face is the most
vascular dermal area of the body. The vascularity of the
external auditory canal has been documented as having
the largest skin temperature gradient [10]. This lends the
external auditory canal to be at significant risk of
developing skin toxicities associated with sorafenib. The
development of bullous lesions in the external auditory
canal is supportive of previous proposed mechanisms of
dermal skin toxicities associated with sorafenib with the
exception of being a pressure point. Our patient developed
Figure 1. Otoscopic exam of the right external auditory
canal. A small 0.4 cm bullous lesion, with no surrounding
erythema.
Figure 2. Otoscopic exam of the left external auditory canal.
A 1.0 cm ruptured bullous lesion with associated bleeding of
the bullous.
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which led to irrigation and increased manipulation of the
external auditory canal. His acute bullous otitis externa
was asymptomatic and responded to withdrawal of the
offending agent.
Conclusion
The list of toxicities of multitargeted tyrosine kinase
inhibitors is growing as use increases in more solid
tumors. Skin toxicities are common when using multi-
targeted tyrosine kinase inhibitors with up to one-third of
patients developing grade 3 toxicities. Otoscopic examina-
tion should be considered in patients that develop hand-
foot and skin toxicities and complain of hearing
disturbances.
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